Sermorelin Dosage Guide

Dosage overview

Dosing notes

Clinical trials in children used 30 mcg/kg/day administered subcutaneously at bedtime (PMID: 8772599). Adult protocols in anti-aging and body composition studies have typically used doses ranging from 100 mcg to 1 mg daily, with most clinical research using weight-based dosing of 10-30 mcg/kg (PMID: 9141536). Community protocols commonly report 200-500 mcg nightly as a starting range. Bedtime administration is supported by research showing GHRH amplifies the natural GH pulse during early slow-wave sleep. Studies demonstrate that GHRH given during the first half of the night increases slow-wave sleep and GH levels, while morning administration does not produce the same sleep-endocrine benefits (PMID: 9089471). Administration on an empty stomach (2+ hours after eating) is widely recommended, as food intake — particularly carbohydrates and fats — can blunt GH release. Cycling protocols are debated. Some clinicians prescribe continuous daily use for 3-6 months followed by a break, while others use 5-days-on/2-days-off schedules. There is limited clinical data supporting one cycling approach over another. The Corpas study showed measurable GH/IGF-I effects within 14 days (PMID: 1379256), but body composition and cognitive changes typically require 3-6 months of consistent use. Reconstitution: Sermorelin should be reconstituted with bacteriostatic water, not sterile water. Direct the water stream against the vial wall, never directly onto the peptide powder. Gently swirl — never shake. Store reconstituted sermorelin refrigerated at 36-46 degrees F and use within 14 days. Never freeze reconstituted peptide. Sermorelin is not FDA-approved for any indication in adults. All adult uses are off-label.

Important safety information

Dosage ranges listed above are based on published clinical trial protocols. Individual dosing should be determined by a qualified healthcare provider based on your specific health profile, goals, and response to treatment.

• Start at the lowest effective dose and titrate up gradually
• Monitor for side effects, especially during dose increases
• Do not exceed researched dose ranges without medical supervision
• This is a research compound — human dosing guidelines are not FDA-established

Research references

• Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy — Journal of Clinical Endocrinology & Metabolism (1996) [PubMed]
• Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency — BioDrugs (1999) [PubMed]
• Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men — Journal of Clinical Endocrinology & Metabolism (1992) [PubMed]
• Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women — Journal of Clinical Endocrinology & Metabolism (1997) [PubMed]
• Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men — Metabolism (1997) [PubMed]
• Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial — Archives of Neurology (2012) [PubMed]
• Treating age-related changes in somatotrophic hormones, sleep, and cognition — Dialogues in Clinical Neuroscience (2001) [PubMed]
• Changes in sleep-endocrine activity after growth hormone-releasing hormone depend on time of administration — Journal of Neuroendocrinology (1997) [PubMed]
• Reduced efficacy of growth hormone-releasing hormone in modulating sleep endocrine activity in the elderly — Neurobiology of Aging (1997) [PubMed]
• Sermorelin: A better approach to management of adult-onset growth hormone insufficiency? — Clinical Interventions in Aging (2006) [PubMed]
• Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males — Translational Andrology and Urology (2020) [PubMed]
• The Safety and Efficacy of Growth Hormone Secretagogues — Sexual Medicine Reviews (2018) [PubMed]
• Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults — Journal of Clinical Endocrinology & Metabolism (2006) [PubMed]
• Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels — American Journal of Men's Health (2017) [PubMed]